drugset / Trial / NCT00217477

Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer

NCT00217477

Phase 1 Completed 34 enrolled Roswell Park Cancer Institute Abbott · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving paricalcitol together with gemcitabine may be an effective treatment for cancer. PURPOSE: This phase I trial is studying the side effects and best dose of paricalcitol when given together with gemcitabine in treating patients with advanced cancer.

Timeline

Start
2004-08
Primary completion
2013-05
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule Intravenous
Subject Paricalcitol Other / unclassified Intravenous